Outlook Therapeutics Inc Stock Today
| OTLK Stock | USD 2.01 0.31 18.24% |
Performance0 of 100
| Odds Of DistressOver 80
|
OUTLOOK THERAPEUTICS is selling for 2.01 as of the 28th of December 2024. This is a 18.24 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.67. OUTLOOK THERAPEUTICS has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 1st of July 2024 and ending today, the 28th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of May 2016 | Category Healthcare | Classification Health Care |
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. The company has 23.66 M outstanding shares of which 3.51 M shares are now shorted by private and institutional investors with about 1.26 trading days to cover. More on OUTLOOK THERAPEUTICS INC
Moving together with OUTLOOK Stock
Moving against OUTLOOK Stock
OUTLOOK Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Russell III | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOUTLOOK THERAPEUTICS can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand OUTLOOK THERAPEUTICS's financial leverage. It provides some insight into what part of OUTLOOK THERAPEUTICS's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
OUTLOOK THERAPEUTICS INC (OTLK) is traded on NASDAQ Exchange in USA. It is located in Building F, Iselin, NJ, United States, 08852 and employs 24 people. OUTLOOK THERAPEUTICS is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 47.55 M. OUTLOOK THERAPEUTICS INC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 23.66 M outstanding shares of which 3.51 M shares are now shorted by private and institutional investors with about 1.26 trading days to cover.
OUTLOOK THERAPEUTICS INC currently holds about 26.02 M in cash with (42.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12.
Check OUTLOOK THERAPEUTICS Probability Of Bankruptcy
Ownership AllocationOUTLOOK THERAPEUTICS owns a total of 23.66 Million outstanding shares. OUTLOOK THERAPEUTICS has large amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check OUTLOOK Ownership Details
OUTLOOK Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Woodline Partners Lp | 2024-09-30 | 151.5 K | |
| Northern Trust Corp | 2024-09-30 | 118.9 K | |
| Federated Hermes Inc | 2024-09-30 | 91.4 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 51.5 K | |
| Lvw Advisors, Llc | 2024-09-30 | 47.7 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 43.7 K | |
| Susquehanna Fundamental Investments, Llc | 2024-06-30 | 41 K | |
| Xtx Topco Ltd | 2024-09-30 | 37.3 K | |
| Goldman Sachs Group Inc | 2024-09-30 | 35.6 K | |
| Great Point Partners Llc | 2024-06-30 | 1.7 M | |
| Tang Capital Management Llc | 2024-09-30 | 1.6 M |
OUTLOOK THERAPEUTICS Historical Income Statement
OUTLOOK Stock Against Markets
OUTLOOK THERAPEUTICS Corporate Management
| Terry Dagnon | Chief Officer | Profile | |
| Balu Balasubramanian | Advisor | Profile | |
| Jeffrey Evanson | Chief Officer | Profile | |
| Jedd Comiskey | Senior Europe | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OUTLOOK THERAPEUTICS INC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OUTLOOK THERAPEUTICS. If investors know OUTLOOK will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OUTLOOK THERAPEUTICS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.06) | Revenue Per Share 0.119 | Quarterly Revenue Growth 6.583 | Return On Assets (0.84) | Return On Equity (0.04) |
The market value of OUTLOOK THERAPEUTICS INC is measured differently than its book value, which is the value of OUTLOOK that is recorded on the company's balance sheet. Investors also form their own opinion of OUTLOOK THERAPEUTICS's value that differs from its market value or its book value, called intrinsic value, which is OUTLOOK THERAPEUTICS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OUTLOOK THERAPEUTICS's market value can be influenced by many factors that don't directly affect OUTLOOK THERAPEUTICS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OUTLOOK THERAPEUTICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if OUTLOOK THERAPEUTICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OUTLOOK THERAPEUTICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.